{"created":"2023-06-19T10:43:26.120143+00:00","id":3661,"links":{},"metadata":{"_buckets":{"deposit":"c73544ed-58da-42e9-bbf5-3d84464dca6a"},"_deposit":{"created_by":11,"id":"3661","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3661"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003661","sets":["30:59:221"]},"author_link":["546","538","2408"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-06-20","bibliographicIssueDateType":"Issued"},"bibliographic_titles":[{},{"bibliographic_title":"Journal of diabetes investigation","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"柏木, 厚典"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"荒木, 信一"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"前川, 聡"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Recent major clinical trials of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three-point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease or advanced renal disease. HF is a major determinant of the prognosis of diabetes patients. Although HF with low ejection fraction can be effectively treated with antihypertensive drugs, these treatments do not reduce mortality in HF patients with preserved ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dysfunction, perivascular fibrosis and stiffness of cardiomyocytes, defined as \"cardiomyopathy\". Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibitors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload, hypertension and cardiac inflammation. In the final part of the present review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2 inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism as a result of ketone body production. Investigations of the beneficial effects of SGLT2 inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried out in preclinical and clinical studies. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"32563214","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1111/jdi.13329"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/jdi.13329","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2020 The Authors. "},{"subitem_rights":"Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. "}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2040-1124","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KASHIWAGI, Atsunori"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"ARAKI, Shin-ichi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"MAEGAWA, Hiroshi"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-20"}],"displaytype":"detail","filename":"jdi.13329.pdf","filesize":[{"value":"564.6 kB"}],"format":"application/pdf","license_note":"This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"jdi.13329","url":"https://shiga-med.repo.nii.ac.jp/record/3661/files/jdi.13329.pdf"},"version_id":"dd2b8431-a348-4ee7-a1b3-82334fa32798"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Heart failure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Sodium-glucose cotransporter 2 inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Type 2 diabetes mellitus.","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients."}]},"item_type_id":"4","owner":"11","path":["221"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-20"},"publish_date":"2020-08-20","publish_status":"0","recid":"3661","relation_version_is_last":true,"title":["Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T12:07:58.656980+00:00"}